Continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) of rapid-acting insulin analogues and detemir in type 1 diabetic (T1D) pregnant women

References

• Jovanovic L, Knops RH, Kim H, et al. Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancy: evidence for a protective adaptation in diabetes. Diab Care 2005;28:1113–17
   PubMed Web of Science ®Google Scholar
• Schaefer UM, Songster G, Xiang A, et al. Congenital malformation in offspring of women with hyperglycemia first detected during pregnancy. Am J Obstet Gynecol 1997;177:1165–17
   PubMed Web of Science ®Google Scholar
• Ehrlich SF, Crites YM, Hedderson MM, et al. The risk of large for gestational age across increasing categories of pregnancy glycemia. Am J Obstet Gynecol 2011;204:240.e1–6
   Web of Science ®Google Scholar
• Plagemann A. Maternal diabetes and perinatal programming. Early Human Develop 2011;87:743–7
   PubMed Web of Science ®Google Scholar
• Jovanovic-Peterson L, Peterson CM, Reed GF, et al. Maternal postprandial blood glucose levels and infant birth weight: the diabetes in early pregnancy study. The National Institute of Child Health and Human Development-diabetes in early pregnancy study. Am J Obstet Gynecol 1991;164:103–11
   PubMed Web of Science ®Google Scholar
• Kinsley B. Achieving better outcomes in pregnancies complicated by type 1 and type 2 diabetes mellitus. Clin Ther 2007;29:S153–60
   Web of Science ®Google Scholar
• Farrar D, Tuffnell DJ, West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev 2007, Issue 3. Review content assessed as up-to-date: 6 September 2011
   Google Scholar
• Castorino K, Paband R, Zisser H, Jovanovic L. Insulin pumps in pregnancy: using technology to achieve normoglycemia in women with diabetes. Curr Diab Rep 2012;12:53–9
   PubMed Web of Science ®Google Scholar
• Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Rec 2004;21:1498–504
   Web of Science ®Google Scholar
• Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614–20
   PubMed Web of Science ®Google Scholar
• Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622–9
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Simpson R, Hylleberg B, et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26:724–36
   PubMed Web of Science ®Google Scholar
• Bartley PC, Bogoev M, Larsen J, Philotheou A. Long term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patient with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin as part at meal: a 2-year, randomized, controlled trial. Diabet Med 2008;25:442–9
   PubMed Web of Science ®Google Scholar
• Durnwald CP, Landon MB. Insulin analogues in the management of the pregnancy complicated by diabetes mellitus. Curr Diab Rep 2011;11:28–34
   PubMed Web of Science ®Google Scholar
• Mathiesen ER, Damm P, Jovanovic L, et al. Basal insulin analogues in diabetic pregnancy: a literature review and baseline results of a randomised controlled trial in type 1 diabetes. Diab Metab Res Rev 2011;27:543–51
   PubMed Web of Science ®Google Scholar
• Torlone E, Di Cianni G, Mannino D, Lapolla A. Insulin analogs and pregnancy: an update. Acta Diabetol 2009;46:163–72
   PubMed Web of Science ®Google Scholar
• Lapolla A, Di Cianni G, Bruttomesso D, et al. Use of insulin detemir in pregnancy: a report on 10 Type 1 diabetic women. Diabet Med 2009;26:1181–2
   PubMed Web of Science ®Google Scholar
• Mathiesen ER, Hod M, Ivanisevic M, et al. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabet Care 2012;35:2012–17
   PubMed Web of Science ®Google Scholar
• Levemir® (insulin detemir [rDNA origin] injection) solution for subcutaneous injection. Initial U.S. Approval: 2005. Revised: 4/2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021536S039lbl.pdf
   Google Scholar
• Di Cianni G, Fatati G, Lapolla A, et al., from Italian Society of Diabetology (SID) Association of Diabetologists (AMD) Italian Association of Dietetics and Clinical Nutrition (AIDNC). Italian Guidelines for nutritional therapy in diabetic pregnancies. Recommendations. 05/2006
   Google Scholar
• Dietary Reference Values of Nutrients and Energy for the Italian population. Revision 2012. Summary of the XXXV National Congress of the Italian Society of Human Nutrition. Bologna; 2012
   Google Scholar
• Rasmussen KM, Yaktine AL. Committee to Reexamine IOM (Institute of Medicine) Pregnancy Weight Guidelines; Food and Nutrition Board; Board on Children, Youth and Families. Institute of Medicine and National Research Council of the National Academies. Weight gain during pregnancy. Reexamining the guidelines. Washington, DC: The National Academic Press; 2009
   Google Scholar
• Parretti E, Mecacci F, Papini M, et al. Third trimester maternal glucose levels from diurnal profiles in nondiabetic pregnancies. Correlation with sonographic parameters of fetal growth. Diabet Care 2001;24:1319–23
   PubMed Web of Science ®Google Scholar
• Parretti E, Carignani L, Cioni R, et al. Sonographic evaluation of fetal growth and body composition in women with different degrees of normal glucose metabolism. Diabet Care 2003;26:2741–8
   PubMed Web of Science ®Google Scholar
• Bernstein IM, Goram MI, Amini SB, Catalano PM. Differential growth of fetal tissue during the second half of pregnancy. Am J Obstet Gynecol 1997;176:28–32
   PubMed Web of Science ®Google Scholar
• Gardosi J, Chang A, Kalyan B, et al. Customised antenatal growth charts. Lancet 1992;339:283–7
   PubMed Web of Science ®Google Scholar
• Volpe L, Pancani F, Aragona M, et al. Continuous subcutaneous insulin infusion and multiple dose insulin injections in Type 1 diabetic pregnant women: a case-control study. Gynecol Endocrinol 2010;26:193–6
   PubMed Web of Science ®Google Scholar
• Bruttomesso D, Bonomo M, Costa S, et al; the IGCSIIP (Italiano Group for Continuous Subcutaneous Insulin Infusion in Pregnancy). Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insuline glargine and multiple daily injections of rapid acting insulin analogues (glargine-MDI). Diabet Metab 2011;37:426–31
   Google Scholar
• Ringholm L, Pedersen-Bjergaard U, Thorsteinsson B, et al. Hypoglycemia during pregnancy in women with type 1 diabetes. Diabet Med 2012;29:558–66
   PubMed Web of Science ®Google Scholar